Empagliflozin targeting the real-world heart failure population

Heart Failure (HF) is a complex syndrome further aggravated by diabetes mellitus (DM). In the EMPA-REG OUTCOME trial, enrolling 7020 patients with diabetes and established cardiovascular (CV) disease, HbA1c 7.0-10% and estimated glomerular filtration rate (eGFR) ≥30mL/min/1.73m2, empagliflozin significantly reduced hospitalization for HF1. However, only 10.1% had HF at baseline. We aimed to investigate whether patients with diabetes admitted for decompensated HF in a “real-world” setting would be enrolled per the trial's main key inclusion and exclusi on criteria.

Source: Journal of Cardiac Failure - February 8, 2019 Category: Cardiology Authors: Bruno M.L. Rocha, Rita V. Gomes, Gon çalo J.L. Cunha, Gonçalo Mendes, Rui Morais, L. Campos, Inês Araújo, M. Cândida Fonseca Tags: Research Letter Source Type: research